Prevention of Contagious Caprine Pleuropneumonia by Immunoprophylaxis: Practical Approach Through Quality Caprine Mycoplasma Vaccines Production for the Prevention of Ccpp in Small Ruminants

A compendium of quality Caprine Mycoplasma vaccine production is presented with respect to its stability, safety and sterility studies and in-vivo clinical trial of plain formalin inactivated (FIV) and two adjuvanted vaccines (AAV & OEV)belong to Mycoplasma mycoides subspecies capri (PG3) also known as Mycoplasma capricolum sub spp capricolum in goats. The growth was obtained in PPLO broth containing yeast extract (1%), horse serum (20%) and thallium acetate. Each dose of 2.5ml vaccine contains not less than 0.10 mg of protein. All the vaccines were found stable upto 6 months under refrigeration temperature. Indirect haemagglutination test (IHA) and complement fixation tests (CFT) were applied to determine humoral immune response in goats. Overall vaccine results showed that OEV had produced higher CFT antibody response. Whereas, AAV alone and as booster showed non significant variation in the CFT and IHA antibody response. This is the first reported effort to develop adjuvanted vaccines against Mycoplasma mycoides subspecies capri (PG3) to develop immunity in goats. Moreover, OEV and AAV proved helpful in providing solid immunity which lasted for more than a year.